Terms: = Uterine cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
39 results:
1. Mismatch repair gene
Zhou LZ; Xiao HQ; Chen J
Front Immunol; 2024; 15():1302797. PubMed ID: 38390329
[TBL] [Abstract] [Full Text] [Related]
2. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.
Rocha Martins P; Luciano Pereira Morais K; de Lima Galdino NA; Jacauna A; Paula SOC; Magalhães WCS; Zuccherato LW; Campos LS; Salles PGO; Gollob KJ
Sci Rep; 2023 Dec; 13(1):22634. PubMed ID: 38114557
[TBL] [Abstract] [Full Text] [Related]
3. Advances in molecular mechanism of HPV16 E5 oncoprotein carcinogenesis.
Chen B; Zhao L; Yang R; Xu T
Arch Biochem Biophys; 2023 Sep; 745():109716. PubMed ID: 37553047
[TBL] [Abstract] [Full Text] [Related]
4. Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial cancers.
Sulaiman R; De P; Aske JC; Lin X; Dale A; Koirala N; Gaster K; Espaillat LR; Starks D; Dey N
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446260
[TBL] [Abstract] [Full Text] [Related]
5. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
6. Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.
Liu Y; Dong C; He X; Wu P; Shu Y; Chen L
BMC Nephrol; 2023 Mar; 24(1):51. PubMed ID: 36899322
[TBL] [Abstract] [Full Text] [Related]
7. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract] [Full Text] [Related]
8. Convolutional Neural Networks for Classifying Cervical cancer Types Using Histological Images.
Li YX; Chen F; Shi JJ; Huang YL; Wang M
J Digit Imaging; 2023 Apr; 36(2):441-449. PubMed ID: 36474087
[TBL] [Abstract] [Full Text] [Related]
9. New Perspectives in Therapeutic Vaccines for HPV: A Critical Review.
Gardella B; Gritti A; Soleymaninejadian E; Pasquali MF; Riemma G; La Verde M; Schettino MT; Fortunato N; Torella M; Dominoni M
Medicina (Kaunas); 2022 Jun; 58(7):. PubMed ID: 35888579
[TBL] [Abstract] [Full Text] [Related]
10. Endometrial cancer-Infiltrating Mesenchymal Stem Cells Exhibit Immunosuppressive Effects.
Wang KH; Chang YH; Harnod T; Ding DC
Cell Transplant; 2022; 31():9636897221104452. PubMed ID: 35712817
[TBL] [Abstract] [Full Text] [Related]
11. Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical cancer treatment.
Wu J; Lakomy DS; Fellman BM; Salcedo MP; Sood AK; Jhingran A; Klopp AH; Iyer RB; Jimenez C; Colbert LE; Eifel PJ; Schmeler KM; Lin LL
Pract Radiat Oncol; 2022; 12(5):e423-e433. PubMed ID: 35390531
[TBL] [Abstract] [Full Text] [Related]
12. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract] [Full Text] [Related]
13. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.
Pötter R; Tanderup K; Schmid MP; Jürgenliemk-Schulz I; Haie-Meder C; Fokdal LU; Sturdza AE; Hoskin P; Mahantshetty U; Segedin B; Bruheim K; Huang F; Rai B; Cooper R; van der Steen-Banasik E; Van Limbergen E; Pieters BR; Tan LT; Nout RA; De Leeuw AAC; Ristl R; Petric P; Nesvacil N; Kirchheiner K; Kirisits C; Lindegaard JC;
Lancet Oncol; 2021 Apr; 22(4):538-547. PubMed ID: 33794207
[TBL] [Abstract] [Full Text] [Related]
14. treatment of uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
[TBL] [Abstract] [Full Text] [Related]
15. PD-L1 and PD-L2 Expression in Cervical cancer: Regulation and Biomarker Potential.
Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
Front Immunol; 2020; 11():596825. PubMed ID: 33424844
[TBL] [Abstract] [Full Text] [Related]
16. Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine.
Zhao X; Yang F; Mariz F; Osen W; Bolchi A; Ottonello S; Müller M
PLoS Pathog; 2020 Sep; 16(9):e1008827. PubMed ID: 32886721
[TBL] [Abstract] [Full Text] [Related]
17. Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer.
Cosper PF; McNair C; González I; Wong N; Knudsen KE; Chen JJ; Markovina S; Schwarz JK; Grigsby PW; Wang X
Int J Cancer; 2020 Apr; 146(7):2047-2058. PubMed ID: 31732968
[TBL] [Abstract] [Full Text] [Related]
18. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
Martins PR; Machado CMT; Coxir SA; de Oliveira AJ; Moreira TB; Campos LS; Alcântara R; de Paula SOC; de Oliveira Salles PG; Gollob KJ; Magalhães WCS
Exp Mol Pathol; 2019 Dec; 111():104314. PubMed ID: 31654628
[TBL] [Abstract] [Full Text] [Related]
19. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
[TBL] [Abstract] [Full Text] [Related]
20. Serum Immune Profiling for Early Detection of Cervical Disease.
Ewaisha R; Panicker G; Maranian P; Unger ER; Anderson KS
Theranostics; 2017; 7(16):3814-3823. PubMed ID: 29109779
[TBL] [Abstract] [Full Text] [Related]
[Next]
